IKBKB and ovarian cancer: We first evaluated the effect of BEZ235 and Bay 65–1942 treatment individually or in combination on the PI3K/mTOR signaling and IKKβ target gene expression in FUOV1, NIH:OVCAR3 and IGROV1 ovarian cancer cells.